相关实验视频
Updated: May 29, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.3K
在长效胰岛素研究中,如何提高euglycemic葡萄糖测试的质量?
Yi Yang1, Fu Kuang1, XueYing Zhu1
1Department of Phase I Clinical Trial Center, The Second Affiliated Hospital of ChongQing Medical University, ChongQing, China.
Trials
|February 1, 2025
概括
长效胰岛素的euglycemic紧试验质量可以使用血糖变化系数 (CVBG) 来评估. ≤3.5%的CVBG表明测试质量优越,药理动力学和药理动力学评估可靠.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 临床试验 临床试验
背景情况:
- 欧糖测试是评估长效胰岛素的药理动力学和药理动力学的最佳方法.
- 目前还没有标准化的方法来评估紧剂试验的质量,特别是长效胰岛素的质量.
- 监管指南缺乏评估紧固件试验质量的具体门.
研究的目的:
- 建立长效胰岛素euglycemic葡萄糖合剂试验的评估标准.
- 提高该测试方法的整体质量和可靠性.
主要方法:
- 53名健康的志愿者接受了insulin degludec,并接受了24小时的euglycemic紧测试.
- 志愿者根据血糖变化系数 (CVBG ≤3.5%对比>3.5%) 和C-降低率 (<50%对比≥50%) 进行分组.
- 试验质量,药理动力学和药理动力学在各组之间进行了比较.
主要成果:
- 与CVBG>3.5%相比,CVBG≤3.5%与显著更好的紧固件测试质量相关.
- CVBG与葡萄糖外流量指标 (GEFTR,持续时间,AUC) 有积极的相关性.
- 降低C率≥50%表明足够的内源性胰岛素抑制,如果CVBG保持低,对质量的影响最小.
结论:
- 血糖变化系数 (CVBG) ≤3.5%被提议作为评估长效胰岛素euglycemic紧试验质量的可靠标准.
- 这种CVBG值确保了对准确的药理动力学和药理动力学评估的卓越测试质量.
- 适当的内源性胰岛素抑制 (C-降低≥50%) 是很重要的,但低血糖波动 (低CVBG) 是可靠结果的关键.
相关概念视频
Oral Hypoglycemic Agents: Glinides
133
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
133
Glucagon-like Receptor Agonists
292
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
292
Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
Insulin Formulations: Types and Delivery
162
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
162
Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149

